Aberrant casein kinase II in Alzheimer's disease

doi:10.1016/0006-8993(90)90282-G

Brain Research

Volume 507, Issue 2, 22 January 1990, Pages 273-280

https://doi.org/10.1016/0006-8993(90)90282-G Get rights and content

Abstract

Abnormal protein phosphorylation has been identified in Alzheimer's disease (AD) for several proteins including a M_r 60,000 protein, a M_r 86,000 protein and a microtubule-associated protein τ. The M_r 86,000 protein is phosphorylated by protein kinase C, whereas protein kinases responsible for other aberrant phosphorylation reactions are not known. In addition to protein kinase C, another kinase, casein kinase II (CK-II), has now been shown to be aberrant in AD. The spermine-dependent CK-II activity is reduced by 84% in AD and the amount of CK-II as determined by its immunoreactivity on a Western blot is reduced by 63%. Furthermore, the distribution of CK-II in AD is altered. Although the neuronal cell body reacts well with CK-II antisera in the normal cortex. the non-tangle-bearing neurons in the AD cortex showed a 15–30% decrease in anti-CK-II immunoreactivity. The neurofibrillary tangles, on the other hand, stain very strongly with rabbit anti-CK-II and indicates that CK-II may be involved in the pathology of AD. The study of CK-II immunoreactivity for dementing diseases other than AD revealed a similar reduction, suggesting the CK-II involvement in the common process of neurodegeneration.

Reference (28)

BancherC. et al.
Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease
Brain Research
(1989)
ColeG. et al.
An antiserum against amyloid β-protein precursor detects a unique peptide in Alzheimer brain
Neurosci. Lett.
(1989)
DahmusM.E.
Calf thymus RNA polymerases I and II do not contain subunits structurally related to casein kinases I and II
J. Biol. Chem.
(1981)
HathawayG.M. et al.
Inhibition of casein kinase II by heparin
J. Biol. Chem.
(1980)
HathawayG.M. et al.
Casein kinases — multipotential protein kinases
Curr. Top. Cell. Reg.
(1982)
HathawayG.M. et al.
Regulation of casein kinase II by 2,3-biophosphyglycerate in erythroid cells
J. Biol. Chem.
(1984)
MarchioriF. et al.
Synthetic peptide substrates for casein kinase 2. Assessment of minimum structural requirements for phosphorylation
Biochim. Biophys. Acta
(1988)
MeggioF. et al.
Partially dephosphorylated phosphopeptide AcSer(P)-Ser(P)-Ser(P) is an excellent substrate for casein kinase-2
FEBS Lett.
(1988)
MeggioF. et al.
Phosphorylation of phosvitin by casein kinase-2 provides the evidence that phosphoserines can replace carboxylic amino acids as specificity determinants
Biochim. Biophys. Acta
(1988)
MeggioF. et al.
Polyglutanyl peptides; a new class of inhibitors of type-2 casein kinases
FEBS Lett.
(1983)

PfaffM. et al.

Casein kinase II accumulation in the nucleolus and its role in nucleolar phosphorylation

Biochim. Biophys. Acta

(1988)

BraakH. et al.

Neuropil threads occur in dendrites of tangle-bearing nerve cells

Neuropathol. Appl. Neurobiol.

(1988)

CohenP.

Protein phosphorylation and hormone action

ColeG. et al.

Decreased levels of protein kinase C in Alzheimer brain

Brain Research

(1988)

Cited by (96)

CK2 negatively regulates the extinction of remote fear memory
2024, Behavioural Brain Research
Cognitive behavioral therapy, rooted in exposure therapy, is currently the primary approach employed in the treatment of anxiety-related conditions, including post-traumatic stress disorder (PTSD). In laboratory settings, fear extinction in animals is a commonly employed technique to investigate exposure therapy; however, the precise mechanisms underlying fear extinction remain elusive. Casein kinase 2 (CK2), which regulates neuroplasticity via phosphorylation of its substrates, has a significant influence in various neurological disorders, such as Alzheimer’s disease and Parkinson’s disease, as well as in the process of learning and memory. In this study, we adopted a classical Pavlovian fear conditioning model to investigate the involvement of CK2 in remote fear memory extinction and its underlying mechanisms. The results indicated that the activity of CK2 in the medial prefrontal cortex (mPFC) of mice was significantly upregulated after extinction training of remote cued fear memory. Notably, administration of the CK2 inhibitor CX-4945 prior to extinction training facilitated the extinction of remote fear memory. In addition, CX-4945 significantly upregulated the expression of p-ERK1/2 and p-CREB in the mPFC. Our results suggest that CK2 negatively regulates remote fear memory extinction, at least in part, by inhibiting the ERK-CREB pathway. These findings contribute to our understanding of the underlying mechanisms of remote cued fear extinction, thereby offering a theoretical foundation and identifying potential targets for the intervention and treatment of PTSD.
Development of a novel PET ligand, [<sup>11</sup>C]GO289 targeting CK2 expressed in the brain
2023, Bioorganic and Medicinal Chemistry Letters
Positron emission tomography (PET) is a powerful imaging tool that enables early in vivo detection of Alzheimer's disease (AD). For this purpose, various PET ligands have been developed to image β-amyloid and tau protein aggregates characteristically found in the brain of AD patients. In this study, we initiated to develop another type of PET ligand that targets protein kinase CK2 (formerly termed as casein kinase II), because its expression level is known to be altered in postmortem AD brains. CK2 is a serine/threonine protein kinase, an important component of cellular signaling pathways that control cellular degeneration. In AD, the CK2 level in the brain is thought to be elevated by its involvement in both phosphorylation of proteins such as tau and neuroinflammation. Decreased CK2 activity and expression levels lead to β-amyloid accumulation. In addition, since CK2 also contributes to the phosphorylation of tau protein, the expression level and activity of CK2 is expected to undergo significant changes during the progression of AD pathology. Furthermore, CK2 could act as a potential target for modulating the inflammatory response in AD. Therefore, PET imaging targeting CK2 expressed in the brain could be a useful another imaging biomarker for AD. We synthesized and radiolabeled a CK2 inhibitor, [¹¹C]GO289, in high yields from its precursor and [¹¹C]methyl iodide under basic conditions. On autoradiography, [¹¹C]GO289 specifically bound to CK2 in both rat and human brain sections. On baseline PET imaging, this ligand entered and rapidly washed out of the rat brain with its peak activity rather being small (SUV < 1.0). However, on blocking, there was no detectable CK2 specific binding signal. Thus, [¹¹C]GO289 may be useful in vitro but not so in vivo in its current formulation. The lack of detectable specific binding signal in the latter may be due to a relatively high component of nonspecific binding signal in the overall rather weak PET signal, or it may also be related to the known fact that ATP can competitively binds to subunits of CK2, reducing its availability for this ligand. In the future, it will be necessary for PET imaging of CK2 to try out different non-ATP competitive formulations of CK2 inhibitor that can also provide significantly higher in vivo brain penetration.
Characterizing the role of the dark kinome in neurodegenerative disease – A mini review
2021, Biochimica et Biophysica Acta - General Subjects
Citation Excerpt :
Increased levels of CK2 have been detected in the hippocampus and temporal cortex of AD patients compared to non-demented controls [35]. AD hippocampal neurons bearing neurofibrillary tangles (NFT) stain very strongly for CK2 [85–87]. Certainly, the known importance of CK2 and its reported overabundance in the hippocampus could contribute to the vulnerability of this brain region in AD.
Drugs that modulate previously unexplored targets could potentially slow or halt the progression of neurodegenerative diseases. Several candidate proteins lie within the dark kinome, those human kinases that have not been well characterized. Much of the kinome (~80%) remains poorly studied, and these targets likely harbor untapped biological potential.
This review highlights the significance of kinases as mediators of aberrant pathways in neurodegeneration and provides examples of published high-quality small molecules that modulate some of these kinases.
There is a need for continued efforts to develop high-quality chemical tools to illuminate the function of understudied kinases in the brain. Potent and selective small molecules enable accurate pairing of an observed phenotype with a protein target.
The examples discussed herein support the premise that validation of therapeutic hypotheses surrounding kinase targets can be accomplished via small molecules and they can serve as the basis for disease-focused drug development campaigns.
Regulation of HSF1 protein stabilization: An updated review
2018, European Journal of Pharmacology
Citation Excerpt :
According to the study by Jiang et al., the HSF1 protein decrease in AD brains is associated with the decrease in HSF1 mRNA expression (Jiang et al., 2013), which is different from that observed in other neurodegenerative disease models, such as PD and ALS. The contribution of protein degradation should also be considered, as CK2, a previously reported kinase responsible for the phosphorylation-dependent HSF1 degradation (Gomez-Pastor et al., 2017), is found to be implicated in the pathogenesis of AD (Masliah et al., 1992; Iimoto et al., 1990; Perez et al., 2011). For example, the altered CK2 has been shown to promote AD phenotypes via phosphorylation of tau (Masliah et al., 1992).
Heat shock factor 1 (HSF1) is a transcriptional factor that determines the efficiency of heat shock responses (HSRs) in the cell. Given its function has been extensively studied in recent years, HSF1 is considered a potential target for the treatment of disorders associated with protein aggregation. The activity of HSF1 is traditionally regulated at the transcriptional level in which the transactivation domain of HSF1 is modified by extensive array of pos-translational modifications, such as phosphorylation, sumoylation, and acetylation. Recently, HSF1 is also reported to be regulated at the monomeric level. For example, in neurodegenerative disorders such as Huntington's disease and Alzheimer's disease the expression levels of the monomeric HSF1 are found to be reduced markedly. Methylene blue (MB) and riluzole, two clinical available drugs, increase the amount of the monomeric HSF1 in both cells and animals. Since the monomeric HSF1 not only determines the efficiency of HSRs, but exerts protective effects in a trimerization-independent manner, increasing the amount of the monomeric HSF1 via stabilization of HSF1 may be an alternative strategy for the amplification of HSR. However, to date we have no outlined knowledges about HSF1 protein stabilization, though studies regarding the regulation of the monomeric HSF1 have been documented in recent years. Here, we summarize the regulation of the monomeric HSF1 by some previously reported factors, such as synuclein, Huntingtin (Htt), TDP-43, unfolded protein response (UPR), MB and doxorubicin (DOX), as well as their possible mechanisms, aiming to push the understanding about HSF1 protein stabilization.
Effect of histidine protonation state on ligand binding at the ATP-binding site of human protein kinase CK2
2024, Scientific Reports
Protein Kinases and their Inhibitors Implications in Modulating Disease Progression
2023, Protein Journal

View all citing articles on Scopus

View full text

Aberrant casein kinase II in Alzheimer's disease

Abstract

Brain Research

Neurosci. Lett.

J. Biol. Chem.

J. Biol. Chem.

Curr. Top. Cell. Reg.

J. Biol. Chem.

Biochim. Biophys. Acta

FEBS Lett.

Biochim. Biophys. Acta

FEBS Lett.

Biochim. Biophys. Acta

Neuropil threads occur in dendrites of tangle-bearing nerve cells

Neuropathol. Appl. Neurobiol.

Protein phosphorylation and hormone action

Decreased levels of protein kinase C in Alzheimer brain

Brain Research